8:47 AM
 | 
Aug 30, 2018
 |  BC Extra  |  Clinical News

Pfizer ends Phase II trials of DMD candidate

Editor's Note: This article was updated on Aug 30, 2018 at 11:20 AM PDT

Pfizer Inc. (NYSE:PFE) terminated two Phase II trials of domagrozumab (PF-06252616) to treat Duchenne muscular dystrophy after one of the studies missed its primary endpoint. The company will evaluate the data to determine next steps for the humanized mAb against myostatin (MSTN; GDF8), which it had believed was a potential blockbuster.

In the Phase II B5161002 trial evaluating safety and efficacy, domagrozumab showed no significant improvement compared with placebo on the mean change from baseline to one year on a four-stair climb test, missing its primary endpoint. Pfizer said evaluation of all available data, including secondary endpoint results,...

Read the full 468 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >